Ramírez HL, Gómez-Sáenz A, Vega SDC, Arenas R

Language: Spanish
References: 57
Page: 184-195
PDF size: 242.69 Kb.

ABSTRACT

Onychomycosis due to by non-dermatophyte molds have a low frequency but they remain medically important because of their challenge for diagnosis and treatment. With some exceptions, as Fusarium solani and Neoscytalidium dimidiatum, the causal agents are fungi that do not produce keratinases and, they depend on other conditions to produce infection. Fusarium spp., Aspergillus spp., Scopulariopsis spp. and Neoscytalidium dimidiatum are non-dermatophyte fungi difficult to treat, despite the therapeutic alternatives that are currently available.

REFERENCES

1. Cavallera E y Asbati M, Onicomicosis por hongos filamentosos no dermatofitos, Dermatología Venezolana 2006; 44(1): 4-9.

2. Scher RK, Rich P, Pariser D y Elewski B, The epidemiology, etiology, and pathophysiology of onychomycosis, Semin Cutan Med Surg 2013; 32 (2 Suppl 1): 2-4.

3. Ballesté R, Mousqués N y Gezuele E, Onicomicosis: revisión del tema, Revista Médica del Uruguay 2003; 19(2): 93-106.

4. Asbati M, Bell S y Caraballeda E, Onicomicosis por hongos no dermatofitos: estudio retrospectivo en 4 años, Rev Soc Venez Microbiol 2002; 22(2): 147-52.

5. Baran R, Tosti A y Piraccini BM, Uncommon clinical patterns of Fusarium nail infection: report of three cases, Br J Dermatol 1997; 136(3): 424-7.

6. López-Jodra O y Torres-Rodríguez JM, Unusual fungal species causing onychomycosis, Revista Iberoamericana de Micologia 1999; 16(S): 11-5.

7. Bunyaratavej S, Prasertworonun N, Leeyaphan C et al., Distinct characteristics of Scytalidium dimidiatum and non-dermatophyte onychomycosis as compared with dermatophyte onychomycosis, Journal of Dermatology 2015; 42(3): 258-62.

8. Gupta AK, Jain HC, Lynde CW et al., Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicenter canadian survey of 15 000 patients, J Am Acad Dermatol 2000; 43(2 Pt 1): 244-8.

9. Manzano-Gayosso P, Méndez-Tovar LJ, Arenas R et al., Onychomycosis- causing yeasts in four Mexican dermatology centers and their antifungal susceptibility to azolic compounds, Rev Iberoam Micol 2011; 28(1): 32-5.

10. Álvarez P, Enríquez AM, Toro C et al., Three cases of imported dermatomycosis by Scytalidium dimidiatum, Rev Iberoam Micol 2000; 17(3): 102-6.

11. Gupta AK, Drummond-Main C, Cooper EA et al., Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment, J Am Acad Dermatol 2012; 66(3): 494-502.

12. Morales-Cardona CA, Valbuena-Mesa MC, Alvarado Z y Solórzano- Amador A, Non-dermatophyte mould onychomycosis: a clinical and epidemiological study at a dermatology referral centre in Bogota, Colombia, Mycoses 2014; 57(5): 284-93.

13. Tosti A, Piraccini BM y Lorenzi S, Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases, J Am Acad Dermatol 2000; 42(2): 217-24.

14. Martínez-Herrera EO, Arroyo-Camarena S, Tejada-García DL et al., Onychomycosis due to opportunistic molds, Anais Brasileiros de Dermatologia 2015; 90(3): 334-7.

15. Mousavi SA, Esfandiarpour I, Salari S y Shokri H, Onychomycosis due to Fusarium spp. in patient with squamous cell carcinoma: a case report from Kerman, Iran, Journal de Mycologie Medicale 2009; 19(2): 146-9.

16. Arenas R, Micología médica ilustrada, 5ª ed., México, McGraw-Hill, 2014, pp. 345-73.

17. Cuenca-Estrella M, Gómez-López A, Mellado E et al., Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents, Antimicrob Ag Chemotherap 2003; 47(7): 2339-41.

18. Padin C, Fernández-Zeppenfeldt G, Yegres F y Richard-Yegres N, Scytalidium dimidiatum: hongo oportunista para el hombre y árboles de Mangifera indica en Venezuela, Rev Iberoam Micol 2005; 22(3): 172-3.

19. Lacroix C, Kac G, Dubertret L et al., Scytalidiosis in Paris, France, J Am Acad Dermatol 2003; 48(6): 852-6.

20. Cursi IB, Freitas LB, De Neves ML y Silva IC, Onycomychosis due to Scytalidium spp.: a clinical and epidemiologic study at a University Hospital in Rio de Janeiro, Brazil, An Bras Dermatol 2011; 86(4): 689-93.

21. Salas-Campos I, Gross-Martínez N y Carrillo-Dover P, Onicomicosis por hongos fuliginosos, Acta Méd Costarricense 2009; 51(4): 241-4.

22. Guerrero I, Aznar P, García-Martos P y Rodríguez-Iglesias M, Sensibilidad a antifúngicos de especies de Scopulariopsis de origen clínico, Rev Esp Quimioter 2014; 27(1): 17-21.

23. Ranawaka RR, Nagahawatte A y Gunasekara TA, Fusarium onychomycosis: prevalence, clinical presentations, response to itraconazole and terbinafine pulse therapy, and 1-year follow-up in nine cases, Int J Dermatol 2015; 54(11): 1275-82.

24. Arrese JE, Valverde JC y Pierard GE, Un nuevo enfoque sobre la epidemiología de las onicomicosis, Rev Iberoam Micol 2005; 22(3): 163-6.

25. Bonifaz A, Cruz-Aguilar P y Ponce RM, Onychomycosis by molds. Report of 78 cases, Eur J Dermatol 2007; 17(1): 70-2.

26. Arenas R, Dermatología: atlas, diagnóstico y tratamiento, 6ª ed., México, McGraw-Hill, 2015, pp. 485-97.

27. Elewski BE, Onychomycosis: pathogenesis, diagnosis, and management, Clin Microbiol Rev 1998; 11(3): 415-29.

28. Ranawaka RR, De Silva N y Ragunathan RW, Non-dermatophyte mold onychomycosis in Sri Lanka, Dermatol Online J 2012; 18(1): 7.

29. Torres-Guerrero E, Landgrave I, Fernández R y Arenas R, Métodos diagnósticos en onicomicosis. Del koh a la biología molecular, Dermatología CMQ 2010; 8(1): 39-46.

30. Moreno-Coutiño G, Toussaint-Caire S y Arenas R, Clinical, mycological and histological aspects of white onychomycosis, Mycoses, 2010, 53(2): 144-7.

31. English MP, Nails and fungi, Br J Dermatol 1976; 94(6): 697-701.

32. Escobar ML y Carmona-Fonseca J, Onicomicosis por hongos ambientales no dermatofíticos, Rev Iberoam Micol 2003; 20: 6-10.

33. Lee MH, Hwang SM, Suh MK et al., Onychomycosis caused by Scopulariopsis brevicaulis: report of two cases, Annals dermatol 2012; 24(2): 209-13.

34. Carrillo-Muñoz AJ, Tur-Tur C, Hernández-Molina JM et al., Antifúngicos disponibles para el tratamiento de las micosis ungueales, Rev Iberoam Micol 2010; 27(2): 49-56.

35. Ellis D, Watson A, Marley J y Williams T, Non-dermatophytes in onychomycosis of the toenails, Br J Dermatol 1997; 136(4): 490-3.

36. Thomas J, Jacobson G, Narkowicz C et al., Toenail onychomycosis: an important global disease burden, J Clin Pharm Therap 2010; 35(5): 497-519.

37. Manzano-Gayosso P, Méndez-Tovar LJ, Hernández-Hernández F y López-Martínez R, La resistencia a los antifúngicos: un problema emergente en México, Gac Méd Méx 2008; 144(1): 23-6.

38. Farinas MC, Fernández-Sampedro M y Arminanzas C, Formas clínicas y tratamiento de las infecciones causadas por otros hongos filamentosos, Enferm Infec Microbiol Clín 2012; 30(7): 414-9.

39. Thomson P, Anticevic S, Rodríguez H y Silva V, Actividad antifúngica y perfil de seguridad del producto natural derivado del aceite de maravilla ozonizado (amo3) en dermatofitos, Rev Chilena Infectol 2011; 28(6): 512-9.

40. Utako Kimura M, Kaori Takeuchi M, Ayako Kinoshita M y Kenji Takamori M, Treating onychomycoses of the toenail: clinical efficacy of the sub-millisecond 1 064 nm nd:yag laser using a 5 mm spot diameter, J Drugs Dermatol 2012; 11(4): 496-504.

41. Hochman LG, Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed nd:yag 1 064-nm laser, J Cosmetic Laser Therap 2011; 13(1): 2-5.

42. Hees H, Raulin C y Bäumler W, Laser treatment of onychomycosis: an in vitro pilot study, J Deutschen Dermatologischen Gesellschaft 2012; 10(12): 913-7.

43. Rodríguez Zendejas NJ, Fernández Martínez RF, Ávila Romay A y Arenas R, Tratamiento láser en onicomicosis, Dermatología CMQ 2014; 12(1): 7-12.

44. Watanabe D, Kawamura C, Masuda et al., Y Successful treatment of toenail onychomycosis with photodynamic therapy, Arch Dermatol 2008; 144(1): 19-21.

45. Aspiroz C, Cebamanos BF, Rezusta A et al., Terapia fotodinámica aplicada al tratamiento de las onicomicosis. Presentación de un caso y revisión de la literatura, Rev Iberoam Micol 2011; 28(4): 191-3.

46. De la Herrán P, López-Lozano H, Fierro L et al., Paroniquia micótica por Fusarium solani: reporte de caso y revisión de la literatura, Dermatología CMQ 2012; 10(2): 139-42.

47. Moreno G y Arenas R, Other fungi causing onychomycosis, Clin Dermatol 2010; 28: 160-3.

48. Zuluaga CA, Bedout C, Tabares A et al., Behavior of etiologic agents of onychomycosis in a mycology reference laboratory (Medellin 1994- 2003), Med Cutan Iber Lat Am 2005; 33: 251-6.

49. Lim JT, Chua HC y Goh CL, Dermatophyte and non-dermatophyte onychomycosis in Singapore, Australas J Dermatol 1992; 33: 159-63.

50. Gianni C, Cerri A y Crosti C, Case report: unusual clinical features of fingernail infection by Fusarium oxysporum, Mycoses 1997; 40: 455-9.

51. Escobar LM y Carmona FJ, Onicomicosis por hongos ambientales no dermatofitos, Rev Iberoam Micol 2003; 20: 6-10.

52. Dordain-Bigot ML, Baran R, Baixench MT y Basex J, Onychomycose á Fusarium, Ann Dermalol Venereol 1996; 123: 191-3.

53. Midgley G, Moore MK, Cook JC y Phan QG, Mycology of nail disorders, J Am Acad Dermatol 1994; 31: 68-74.

54. Garinet S, Tourret J, Barete S et al., Invasive contaneous Neoscytalidium infections in renal transplant reciepients: a series of five cases, bmc Infections Dieseases 2005; 15: 535.

55. Krishna G, Ma L, Marinho M et al., Determination of posaconazole levels in toenails for adults with onychomycosis following oral treatment with four regimens of posaconazole for 12 or 24 weeks, Antimicrob Gents Chemother 2011; 55: 4424-6.

56. Al-Hatmi AM, Van Diepeningen AD, Curfs-Breuker I et al., Specific antigungal susceptibility profiles of opportunistis in the Fusarium Fujikuroi complex, J Antimicrob Chemother 2015; 70: 1068-71.

57. Al-Hatmi AM, Bonifaz A, Calderón L et al., Proximal subungual onychomycosis caused by Fusarium falciforme successfully cured with posaconazole, Br J Dermatol 2015; 173(1): 253-5.